MarketPulse

protein degradation

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Amphista Therapeutics

Amphista Therapeutics Showcases Next-Gen Cancer Degraders at AACR Meeting

Amphista Therapeutics presents three programs at AACR 2026, including oral presentation on AMX-883 BRD9 degrader for AML treatment.
LLYNVScancer treatmentprotein degradation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arvinas to Showcase ARV-102 Parkinson's Data at Major Neurology Conference

Arvinas will present Phase 1 data for ARV-102, a PROTAC LRRK2 degrader, at AD/PD 2026 conference in Copenhagen, with Phase 1b trial planned for progressive supranuclear palsy.
ARVNPhase 1 clinical trialParkinson's disease